Schizophrenia is a debilitating psychiatric disorder characterized by positive (hallucinations, delusions), negative (lack of motivation, flat affect), and cognitive (impaired memory and attention) symptoms. Aripiprazole, a dual-action antipsychotic, shows promise in enhancing brain structure and memory in schizophrenia, which may have downstream positive effects on negative symptoms and outcome. However, the mechanisms and timing underlying these potential effects have yet to be determined.